RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill宣佈針對埃博拉病毒的新Opaganib中國專利有效期至2035年
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.: 202110229970.9 issued April 29, 2024).
專業生物製藥公司RedHill Biopharma Ltd.（納斯達克股票代碼：RDHL）（“RedHill” 或 “公司”）今天宣佈發佈一份新的中國專利許可通知，該通知涵蓋了中國國家知識產權局（CNIPA）作爲抑制單鏈RNA病毒複製（尤其是埃博拉病病毒）療法的奧帕加尼 [1]，有效期至2035年（中文）專利申請號：202110229970.9（發佈於 2024 年 4 月 29 日）。
資訊熱榜
更新時間